Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
Rena R. Wing,Wei Lang,Thomas A. Wadden,Monika M. Safford,William C. Knowler,Alain G. Bertoni,James O. Hill,Frederick L. Brancati,Anne L. Peters,Lynne E. Wagenknecht +9 more
Reads0
Chats0
TLDR
Modest weight losses of 5 to <10% were associated with significant improvements in CVD risk factors at 1 year, but larger weight losses had greater benefits.Abstract:
OBJECTIVE Overweight and obese individuals are encouraged to lose 5–10% of their body weight to improve cardiovascular disease (CVD) risk, but data supporting this recommendation are limited, particularly for individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS We conducted an observational analysis of participants in the Look AHEAD (Action For Health in Diabetes) study ( n = 5,145, 40.5% male, 37% from ethnic/racial minorities) and examined the association between the magnitude of weight loss and changes in CVD risk factors at 1 year and the odds of meeting predefined criteria for clinically significant improvements in risk factors in individuals with type 2 diabetes. RESULTS The magnitude of weight loss at 1 year was strongly ( P P = 0.79). Compared with weight-stable participants, those who lost 5 to 1c (odds ratio 3.52 [95% CI 2.81–4.40]), a 5-mmHg decrease in diastolic blood pressure (1.48 [1.20–1.82]), a 5-mmHg decrease in systolic blood pressure (1.56 [1.27–1.91]), a 5 mg/dL increase in HDL cholesterol (1.69 [1.37–2.07]), and a 40 mg/dL decrease in triglycerides (2.20 [1.71–2.83]). The odds of clinically significant improvements in most risk factors were even greater in those who lost 10–15% of their body weight. CONCLUSIONS Modest weight losses of 5 toread more
Citations
More filters
Journal ArticleDOI
Sodium-Glucose Co-Transporter 2 Inhibitors and the Potential for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Mellitus
TL;DR: Inhibition of SGLT2 in patients with T2DM may be associated with significant weight loss and BP reduction that are sustainable over the average time span of an investigational clinical study (ie, 3−6 months).
Journal ArticleDOI
Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data.
Carrie McAdam-Marx,J Mukherjee,Brandon K. Bellows,Sudhir Unni,Xiangyang Ye,Uchenna H. Iloeje,Diana I. Brixner +6 more
TL;DR: Weight loss of ≥3% was associated with better glycemic control in patients newly treated for type 2 diabetes and may facilitate efforts to co-manage weight and glycemia in the ambulatory-care setting.
Journal ArticleDOI
The Healthy Hearts and Kidneys (HHK) study: Design of a 2×2 RCT of technology-supported self-monitoring and social cognitive theory-based counseling to engage overweight people with diabetes and chronic kidney disease in multiple lifestyle changes.
Mary Ann Sevick,Kathleen Woolf,Aditya Mattoo,Stuart D. Katz,Huilin Li,David E. St-Jules,Ram Jagannathan,Lu Hu,Mary Lou Pompeii,Lisa Ganguzza,Zhi Li,Alex Sierra,Stephen Williams,David S. Goldfarb +13 more
TL;DR: The study design, methods, and approaches used to assure information security for this ongoing clinical trial are described and determine the impact of randomization assignment on weight loss success and 24-hour urinary excretion of sodium and phosphorus.
Journal ArticleDOI
Obesity and the Cardiorenal Metabolic Syndrome: Therapeutic Modalities and Their Efficacy in Improving Cardiovascular and Renal Risk Factors.
TL;DR: The role of different treatment options in the management of obesity and its comorbidities are discussed, with a focus on recently approved drugs and the emerging role of bariatric surgery.
Journal ArticleDOI
Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11.
Enzo Bonora,Juan P. Frias,Francisco J. Tinahones,Joanna Van,Raleigh E. Malik,Zhuoxin Yu,Reema Mody,Angelyn Bethel,Anita Y. M. Kwan,David A. Cox +9 more
TL;DR: The AWARD-11 trial as discussed by the authors evaluated the impact of dulaglutide 3.0 and 4.5 mg on body weight in patients with type 2 diabetes.
References
More filters
Journal ArticleDOI
Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge
TL;DR: A method for estimating the cholesterol content of the serum low-density lipoprotein fraction (Sf0-20) is presented and comparison of this suggested procedure with the more direct procedure, in which the ultracentrifuge is used, yielded correlation coefficients of .94 to .99.
Journal Article
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults : the evidence report
Journal ArticleDOI
Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery
TL;DR: A prospective, controlled Swedish Obese Subjects Study involved obese subjects who underwent gastric surgery and contemporaneously matched, conventionally treated obese control subjects, which reported follow-up data for subjects who had been enrolled for at least 2 years or 10 years before the analysis.
Journal ArticleDOI
Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates
Frank M. Sacks,George A. Bray,Vincent J. Carey,Steven R. Smith,Donna H. Ryan,Stephen D. Anton,Katherine McManus,Catherine M. Champagne,Louise M. Bishop,Nancy Laranjo,Meryl S. LeBoff,Jennifer Rood,Lilian de Jonge,Frank L. Greenway,Catherine M. Loria,Eva Obarzanek,Donald A. Williamson +16 more
TL;DR: Low-calorie diets result in clinically meaningful weight loss regardless of which macronutrients they emphasize, and improved lipid-related risk factors and fasting insulin levels.
Journal ArticleDOI
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes: One-Year Results of the Look AHEAD Trial
Mark A. Espeland,Xavier Pi-Sunyer,George L. Blackburn,Frederick L. Brancati,George A. Bray,Renee Bright,Jeanne M. Clark,Jeffrey M. Curtis,John P. Foreyt,Kathryn Graves,Steven M. Haffner,Barbara Harrison,James O. Hill,Edward S. Horton,John M. Jakicic,Robert W. Jeffery,Karen C. Johnson,Steven E. Kahn,David E. Kelley,Abbas E. Kitabchi,William C. Knowler,Cora E. Lewis,Barbara J. Maschak-Carey,Brenda Montgomery,David M. Nathan,Jennifer Patricio,Anne L. Peters,J. Bruce Redmon,Rebecca S. Reeves,Donna H. Ryan,Monika M. Safford,Brent Van Dorsten,Thomas A. Wadden,Lynne E. Wagenknecht,Jacqueline Wesche-Thobaben,Rena R. Wing,Susan Z. Yanovski +36 more
TL;DR: At 1 year, ILI resulted in clinically significant weight loss in people with type 2 diabetes and was associated with improved diabetes control and CVD risk factors and reduced medicine use in ILI versus DSE.
Related Papers (5)
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society
Michael D. Jensen,Donna H. Ryan,Caroline M. Apovian,Jamy D. Ard,Anthony G. Comuzzie,Karen A. Donato,Frank B. Hu,Van S. Hubbard,John M. Jakicic,Robert F. Kushner,Catherine M. Loria,Barbara E. Millen,Cathy Nonas,F. Xavier Pi-Sunyer,June Stevens,Victor J. Stevens,Thomas A. Wadden,Bruce M. Wolfe,Susan Z. Yanovski +18 more